Bio-Path Holdings Announces Publication in Biomedicines - BioSpace

Bio-Path Holdings announces publication in 'Biomedicines' on BP1003's broad anti-tumor effect in solid tumors like breast, ovarian, and pancreatic cancer. BP1003 targets STAT3 mRNA, enhancing stability and cellular uptake, potentially improving chemotherapy efficacy in various cancers.